Table 6. Multivariate analysis of breast cancer survival.
| Included parameters | Disease-free survival | Overall survival | ||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95% CI | P-value | Hazard ratio | 95% CI | P-value | |
| T stage | 0.011 | 0.107 | ||||
| T1 versus T2–3 | 3.801 | 1.361–10.61 | 2.021 | 0.859–4.752 | ||
| N stage | 0.183 | 0.911 | ||||
| N0 versus N1–3 | 1.848 | 0.748–4.565 | 0.953 | 0.413–2.202 | ||
| Age | 0.731 | 0.476 | ||||
| <50 versus ≥50 | 1.167 | 0.483–2.823 | 0.742 | 0.327–1.686 | ||
| Histologic grade | 0.463 | 0.946 | ||||
| I/II versus III | 1.467 | 0.527–4.083 | 1.035 | 0.383–2.797 | ||
| ER status | 0.272 | 0.304 | ||||
| Negative versus Positive | 1.974 | 0.587–6.641 | 1.857 | 0.571–6.043 | ||
| PR status | 0.234 | 0.146 | ||||
| Negative versus Positive | 1.989 | 0.641–6.170 | 2.240 | 0.756–6.641 | ||
| HER2 status | 0.979 | 0.459 | ||||
| Negative versus Positive | 1.014 | 0.360–2.858 | 0.688 | 0.256–1.849 | ||
| Ki-67 LI | 0.242 | 0.595 | ||||
| ≤14 versus >14 | 0.540 | 0.191–1.525 | 0.768 | 0.290–2.031 | ||
| HSL | 0.399 | 0.595 | ||||
| Negative versus Positive | 0.410 | 0.051–3.267 | 0.663 | 0.146–3.014 | ||
| PLIN1 | 0.930 | 0.672 | ||||
| Negative versus Positive | 1.072 | 0.227–5.071 | 0.716 | 0.152–3.367 | ||
| FABP4 | 0.319 | 0.276 | ||||
| Negative versus Positive | 2.970 | 0.349–25.29 | 3.270 | 0.387–27.61 | ||
| CPT1 | 0.846 | 0.072 | ||||
| Negative versus Positive | 1.125 | 0.343–3.686 | 2.406 | 0.924–6.262 | ||
| Acyl-CoA oxidase 1 | 0.647 | 0.161 | ||||
| Negative versus Positive | 1.342 | 0.381–4.730 | 2.180 | 0.733–6.481 | ||
| FASN | 0.164 | 0.076 | ||||
| Negative versus Positive | 0.438 | 0.137–1.402 | 0.371 | 0.124–1.109 | ||